101,964 research outputs found
Arterial vasospasm following subarachnoid hemorrhage - Repeat endovascular pharmacotherapy using papaverine
No full text
Terapia combinata con deferxamina e deferiprone nel trattamento delle complicanze cardiache in un paziente affetto da grave emocromatosi giovanile
No full textBi-Directional Axial Transmission measurements applied in a clinical environment (Herne study)
No full textMinonzio J-G, Ramiandrisoa D, Schneider J, Kohut E, Streichhahn M, Stervbo U, et al. (2022) Bi-Directional Axial Transmission measurements applied in a clinical environment. PLoS ONE 17(12): e0277831.
https://doi.org/10.1371/journal.pone.0277831
The objective of this cross-sectional study was to evaluate the performance of a Bi-Directional Axial Transmission (BDAT) device used by trained operators in a clinical environment with older subjects. The device, positioned at one-third distal radius, provides two velocities: VFAS (first arriving signal) and VA0 (first anti-symmetrical guided mode). Moreover, two parameters are obtained from an inverse approach: Ct.Th (cortical thickness) and Ct.Po (cortical porosity), along with their ratio Ct.Po/Ct.Th. The areal bone mineral density (aBMD) was obtained using DXA at the femur and spine
Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH)
No full textJuvenile hemochromatosis (JH) is a rare autosomal recessive disorder of iron metabolism, genetically heterogeneous. In JH, symptomatic organ involvement occurs as early as the second decade of life. Heart failure and/or arrhythmias are the most frequent causes of death. Phlebotomy is the safest, most effective, and most economic therapeutic approach in hemochromatosis patients but is not indicated during the treatment of severe congestive heart failure with unstable hemodynamic status. The treatment of iron overload in these prohibitive clinical situations has to be carried out using iron chelators. We report a case of heart failure in the setting of unrecognized juvenile hemochromatosis successfully treated by the simultaneous administration of deferoxamine and deferiprone. To our knowledge, this is the first patient affected by JH treated with combined chelation regimen
Reversal of hearth failure by deferoxamine and deferiprone combined therapy in a patient affected by severe type juvenile hemochromatosis
No full text- …
